Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction PART 05: Market overview • Five forces analysis PART 06: Pipeline landscape PART 07: Market segmentation by disease type • Renal pruritus • Cholestatic pruritus • Hematologic pruritus • Endocrine pruritus • Oncological pruritus PART 08: Market segmentation by route of administration (ROA) PART 09: Geographical segmentation • Pruritus therapeutic market in Americas • Pruritus therapeutic market in EMEA • Pruritus therapeutic market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Market challenges PART 12: Market trends • Identification of new T-cell subsets (Th17 and Th22) • Incorporation of novel technology for product development • Inorganic growth strategies PART 13: Vendor landscape • Competitive scenario PART 14: Key vendor analysis • Allergan • GlaxoSmithKline • Pfizer • Sanofi • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits  Exhibit 01: Types of pruritus based on causative disease Exhibit 02: Chemical substances that trigger pruritus Exhibit 03: Major diseases that cause pruritus Exhibit 04: Major drug classes that induce pruritus Exhibit 05: Global pruritus therapeutic market drivers Exhibit 06: Global pruritus therapeutic market 2016-2021 ($ millions) Exhibit 07: Opportunity analysis in global pruritus therapeutic market Exhibit 08: Five forces analysis Exhibit 09: Pipeline molecules based on vendors Exhibit 10: Key clinical trials Exhibit 11: Segmentation of global pruritus therapeutic market by disease type 2016 Exhibit 12: Segmentation of global pruritus therapeutic market share by disease type 2016 Exhibit 13: Global renal pruritus therapeutic market 2016-2021 ($ millions) Exhibit 14: Global cholestatic pruritus therapeutic market 2016-2021 ($ millions) Exhibit 15: Global hematologic pruritus therapeutic market 2016-2021 ($ millions) Exhibit 16: Global endocrine pruritus therapeutic market 2016-2021 ($ millions) Exhibit 17: Global oncological pruritus therapeutic market 2016-2021 ($ millions) Exhibit 18: Various ROAs applied for pruritic drugs 2016 Exhibit 19: Segmentation of global pruritus therapeutic market by geography 2016 and 2021 Exhibit 20: Global pruritus therapeutic market revenue by geography 2016-2021 ($ millions) Exhibit 21: Market scenario in Americas Exhibit 22: Pruritus therapeutic market in Americas 2016-2021 ($ millions) Exhibit 23: Market scenario in EMEA Exhibit 24: Pruritus therapeutic market in EMEA 2016-2021 ($ millions) Exhibit 25: Market scenario in APAC Exhibit 26: Pruritus therapeutic market in APAC 2016-2021 ($ millions) Exhibit 27: Prevalence of pruritus in various disease conditions Exhibit 28: Various drugs responsible for inducing pruritus Exhibit 29: Phase III drugs for management of pruritus Exhibit 30: Global sales of Allegra 2008 and 2016 ($ millions) Exhibit 31: Role of newer T-cell subsets in dermatological diseases Exhibit 32: Inorganic growth strategies Exhibit 33: Competitive structure analysis of global pruritus therapeutic market 2016 Exhibit 34: Market penetration of various global pruritus therapeutic manufacturers 2016 Exhibit 35: Strategic success factors of companies in global pruritus therapeutic market Exhibit 36: Allergan: Key highlights Exhibit 37: Allergan: Strength assessment Exhibit 38: Allergan: Strategy assessment Exhibit 39: Allergan: Opportunity assessment Exhibit 40: GlaxoSmithKline: Key highlights Exhibit 41: GlaxoSmithKline: Strength assessment Exhibit 42: GlaxoSmithKline: Strategy assessment Exhibit 43: GlaxoSmithKline: Opportunity assessment Exhibit 44: Pfizer: Key highlights Exhibit 45: Pfizer: Strength assessment Exhibit 46: Pfizer: Strategy assessment Exhibit 47: Pfizer: Opportunity assessment Exhibit 48: Sanofi: Key highlights Exhibit 49: Sanofi: Strength assessment Exhibit 50: Sanofi: strategy assessment Exhibit 51: Sanofi: opportunity assessment

Allergan, GlaxoSmithKline, Pfizer, and Sanofi. Other Prominent Vendors in the market are: Abbott, Ajanta Pharma, Almirall, Astellas Pharma, Bristol-Myers Squibb, CARA Therapeutic, Cipla, Eisai, Eli Lilly, Galderma, Glenmark, Heron Therapeutic, IPCA, Lupin, Merck, Novartis, Sun Pharma, and Takeda Pharmaceutical.